MYCN has been suggested to be a candidate therapeutic target [46,47] since its suppression could provide an alternative to cytotoxic therapy for relapsed neuroblastoma with an inactivated p53 pathway [44]. The gene discussed is MYCN; the disease is neuroblastoma.